TY - JOUR
T1 - Previously diagnosed obstructive sleep apnea is not associated with increased risk of SARS-CoV-2 infection in community-dwelling older adults living in a highly endemic setting
AU - Del Brutto, Oscar H.
AU - Mera, Robertino M.
AU - Castillo, Pablo R.
AU - Recalde, Bettsy Y.
AU - Costa, Aldo F.
N1 - Publisher Copyright:
© 2021 Elsevier B.V.
PY - 2021/6
Y1 - 2021/6
N2 - Objective: In view of the high prevalence of obstructive sleep apnea (OSA) and the increasing global pandemic of SARS-CoV-2 infection, it is likely that many patients with OSA get exposed to this virus. Besides theoretical assumptions, there is no evidence that OSA may favor SARS-CoV-2 acquisition or may lead to a more severe disease. Taking the opportunity of the Atahualpa Project cohort, we aimed to assess the relationship between previously diagnosed OSA and SARS-CoV-2 infection in older adults living in rural Ecuador. Patients and methods: SARS-CoV-2 antibodies were determined in 180 individuals aged > 60 years that underwent polysomnography previously to this novel pandemic. Those with OSA remained untreated due to income limitations. Exposure-effect models were fitted with OSA as the exposure, SARS-CoV-2 seropositivity and symptomatology as the outcomes, and confounders – age, gender, obesity, arterial hypertension, diabetes mellitus, hypercholesterolemia, individuals per house, home confinement – as independent variables. Results: A total of 87 (48%) individuals were seropositive to SARS-CoV-2, 77% of whom were symptomatic. The mean apnea/hypopnea index was 11.1 ± 11.7 episodes per hour, with 83 (46%) individuals having mild, and 38 (21%) moderate-to-severe OSA. Exposure-effect models demonstrated lack of relationship between OSA and SARS-CoV-2 seropositivity and symptomatology. Conclusions: This study shows no relationship between history of OSA and SARS-CoV-2 seropositivity or symptomatology, opposing previous suggestions that persons with OSA are more prone to acquire the infection and have a more severe disease.
AB - Objective: In view of the high prevalence of obstructive sleep apnea (OSA) and the increasing global pandemic of SARS-CoV-2 infection, it is likely that many patients with OSA get exposed to this virus. Besides theoretical assumptions, there is no evidence that OSA may favor SARS-CoV-2 acquisition or may lead to a more severe disease. Taking the opportunity of the Atahualpa Project cohort, we aimed to assess the relationship between previously diagnosed OSA and SARS-CoV-2 infection in older adults living in rural Ecuador. Patients and methods: SARS-CoV-2 antibodies were determined in 180 individuals aged > 60 years that underwent polysomnography previously to this novel pandemic. Those with OSA remained untreated due to income limitations. Exposure-effect models were fitted with OSA as the exposure, SARS-CoV-2 seropositivity and symptomatology as the outcomes, and confounders – age, gender, obesity, arterial hypertension, diabetes mellitus, hypercholesterolemia, individuals per house, home confinement – as independent variables. Results: A total of 87 (48%) individuals were seropositive to SARS-CoV-2, 77% of whom were symptomatic. The mean apnea/hypopnea index was 11.1 ± 11.7 episodes per hour, with 83 (46%) individuals having mild, and 38 (21%) moderate-to-severe OSA. Exposure-effect models demonstrated lack of relationship between OSA and SARS-CoV-2 seropositivity and symptomatology. Conclusions: This study shows no relationship between history of OSA and SARS-CoV-2 seropositivity or symptomatology, opposing previous suggestions that persons with OSA are more prone to acquire the infection and have a more severe disease.
KW - Apnea hipopnea index
KW - Coronavirus-19
KW - Obstructive sleep apnea
KW - Population study
KW - SARS-CoV-2
UR - https://www.scopus.com/pages/publications/85104654656
U2 - 10.1016/j.clineuro.2021.106639
DO - 10.1016/j.clineuro.2021.106639
M3 - Artículo
C2 - 33901750
AN - SCOPUS:85104654656
SN - 0303-8467
VL - 205
JO - Clinical Neurology and Neurosurgery
JF - Clinical Neurology and Neurosurgery
M1 - 106639
ER -